CharlesLanceCoweyMD

Oncology • Dallas, TX

Genitourinary Oncology, Hematologic Oncology, Melanoma

Texas Oncology, PA/Medical Oncologist

Join to view full profile

Dr. Cowey is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Cowey's full profile

Already have an account?

Office
3410 Worth St
Dallas, TX 75246
Phone+1 214-370-1000

Fax+1 214-370-1202

Education & Training

University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Alabama Medical CenterResidency, Internal Medicine, 2003 - 2006
University of Texas Medical Branch School of MedicineClass of 2003

Certifications & Licensure

TX State Medical License 2009 - 2024
NC State Medical License 2006 - 2009
AL State Medical License 2005 - 2006
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Sep 16
Active, not recruiting
Phase 3
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2019 Dec 12
Completed
Phase 1, Phase 2
Roles: Principal Investigator
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) Start of enrollment: 2019 Jul 18
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

47 citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
James Larkin, Michele Del Vecchio, Mario Mandalá, Helen Gogas, Ana M Arance Fernandez
Clinical Cancer Research. 2023-09-01
48 citations
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhi...
Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella, Rahima Jamal, Lars Ny
Journal of Clinical Oncology. 2023-01-01
16 citations
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
James Larkin, Jeffrey Weber, Michele Del Vecchio, Helen Gogas, Ana M Arance
European Journal of Cancer. 2022-09-01

Press Mentions

Dallas Clinical Trial Explores Slowing Skin Cancer Recurrence with COVID-19 TechnologyApril 23rd, 2024
Dallas Clinical Trial Explores Slowing Skin Cancer Recurrence with COVID-19 TechnologyApril 23rd, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member